Infections in children treated with biological agents

Pediatric Infectious Disease Journal

Volumn 32, Issue 3, 2013, Pages 284-288

  Woerner, Andreas ^a,b   Ritz, Nicole ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ABDOMINAL ABSCESS; APPENDICITIS; ASEPTIC MENINGITIS; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BRONCHITIS; CELLULITIS; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DENGUE; DRUG SAFETY; ENTEROCOLITIS; FLU LIKE SYNDROME; FURUNCULOSIS; GASTROENTERITIS; GROUP A STREPTOCOCCAL INFECTION; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTION RISK; INFLUENZA A (H1N1); JOINT EFFUSION; JUVENILE RHEUMATOID ARTHRITIS; LUNG TUBERCULOSIS; MONONUCLEOSIS; MYCOPLASMOSIS; ORBIT CELLULITIS; OTITIS MEDIA; PARAINFLUENZA VIRUS INFECTION; PERITONITIS; PHARYNGITIS; PILONIDAL SINUS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROSTHESIS INFECTION; PSEUDOMEMBRANOUS COLITIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCARLET FEVER; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; VIRAL GASTROENTERITIS; VIRUS INFECTION; VIRUS PNEUMONIA; YERSINIA INFECTION;

AUTOIMMUNE DISEASES; BIOLOGICAL AGENTS; CHILD; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84876254961     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182833cbb     Document Type: Review

References (40)

1. Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1260-1263.
2. Wallace CA, Giannini EH, Spalding SJ, et al.; Childhood Arthritis and Rheumatology Research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012-2021.
3. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794.
4. Horneff G. Paediatric rheumatic disease: Biologic therapy and risk of infection in children with JIA. Nat Rev Rheumatol. 2012;8:504-505.
5. Beukelman T, Xie F, Chen L, et al.; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:2773-2780.
6. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-769.
7. Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48:218-226.
8. Lovell DJ, Reiff A, Jones OY, et al.; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987-1994.
9. Lovell DJ, Reiff A, Ilowite NT, et al.; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-1504.
10. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152.
11. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635-641.
12. Giannini EH, Ilowite NT, Lovell DJ, et al.; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794-2804.
13. Horneff G, De Bock F, Foeldvari I, et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519-525.
14. Bracaglia C, Buonuomo PS, Tozzi AE, et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol. 2012;39:1287-1290.
15. Ruperto N, Lovell DJ, Cuttica R, et al.; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-c ourse juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096-3106.
16. Ruperto N, Lovell DJ, Cuttica R, et al.; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718-722.
17. Hyams J, Crandall W, Kugathasan S, et al.; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165.
18. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651-662.
19. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111.
20. Tschudy J, Michail S. Disseminated histoplasmosis and Pneumocystis pneumonia in a child with Crohn disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2010;51:221-222.
21. Trachana M, Pratsidou-Gertsi P, Pardalos G, et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40:101-107.
22. Lovell DJ, Ruperto N, Goodman S, et al.; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N EnglJ Med. 2008;359:810-820.
23. Imagawa T, Takei S, Umebayashi H, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31:1713-1721.
24. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143:365-374.e2.
25. Salgado E, Gómez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol. 2011;7:329-340.
26. Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-299.
27. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.
28. Armbrust W, Kamphms SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43:527-529.
29. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-1206.
30. Ayaz NA, Demirkaya E, Bilginer Y, et al. Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol. 2010;29:389-392.
31. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129-137.
32. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multi-center series. Arthritis Rheum. 2011;63:545-555.
33. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-754.
34. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoin-flammatory Muckle-Wells syndrome. Arthritis Rheum. 2011;63:840-849.
35. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006.
36. De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic idiopathic juvenile arthritis (SJIA): tender 52-week data. Pediatr Rheumatology. 2011;9(suppl 1):P164.
37. Ruperto N, Lovell DJ, Quartier P, et al.; Paedi-atric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383-391.
38. Ruperto N, Lovell DJ, Quartier P, et al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792-1802.
39. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituxi-mab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163-1172.
40. Heijstek MW, Ott de Bruin LM, Bijl M, et al.; EULAR. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704-1712.